Want to see HK:2161 full AI Analyst Report?
JBM (Healthcare) Ltd. (2161) Ratios
JBM (Healthcare) Ltd. Ratios
HK:2161's free cash flow for Q4 2025 was $45.83M. For the 2025 fiscal year, HK:2161's free cash flow was decreased by $-17.94M and operating cash flow was $63.77M. See a summary of the company’s cash flow.
| Ratios | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.90 | 1.61 | 1.66 | 2.06 | 1.70 |
| Quick Ratio | 1.59 | 1.32 | 1.25 | 1.69 | 1.42 |
| Cash Ratio | 0.47 | 0.73 | 0.64 | 0.54 | 0.78 |
| Solvency Ratio | 0.40 | 0.65 | 0.48 | 0.20 | 0.27 |
| Operating Cash Flow Ratio | 0.59 | 0.81 | 0.86 | 0.47 | 0.75 |
| Short-Term Operating Cash Flow Coverage | 1.32 | 1.51 | 2.69 | 1.00 | 1.60 |
| Net Current Asset Value | $ -143.33M | $ 71.19M | $ 791.00K | $ -98.56M | $ -41.01M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.11 | 0.10 | 0.16 | 0.13 |
| Debt-to-Equity Ratio | 0.36 | 0.16 | 0.14 | 0.23 | 0.18 |
| Debt-to-Capital Ratio | 0.27 | 0.14 | 0.12 | 0.19 | 0.15 |
| Long-Term Debt-to-Capital Ratio | 0.19 | 0.00 | 0.04 | 0.11 | 0.06 |
| Financial Leverage Ratio | 1.63 | 1.43 | 1.43 | 1.43 | 1.42 |
| Debt Service Coverage Ratio | 2.06 | 1.68 | 2.42 | 1.16 | 0.98 |
| Interest Coverage Ratio | 21.71 | 55.12 | 20.50 | 5.68 | 8.26 |
| Debt to Market Cap | 0.17 | 0.10 | 0.14 | 0.22 | 0.16 |
| Interest Debt Per Share | 0.50 | 0.22 | 0.16 | 0.25 | 0.21 |
| Net Debt to EBITDA | 0.90 | -0.11 | -0.03 | 1.70 | 0.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 55.78% | 52.88% | 52.14% | 35.04% | 36.12% |
| EBIT Margin | 30.40% | 31.46% | 26.74% | 9.15% | 16.36% |
| EBITDA Margin | 36.36% | 38.15% | 34.04% | 20.72% | 21.41% |
| Operating Profit Margin | 30.40% | 31.45% | 26.87% | 8.95% | 13.02% |
| Pretax Profit Margin | 30.21% | 30.89% | 25.43% | 8.01% | 15.15% |
| Net Profit Margin | 24.09% | 25.22% | 20.12% | 6.06% | 10.97% |
| Continuous Operations Profit Margin | 25.20% | 25.91% | 21.16% | 5.74% | 12.17% |
| Net Income Per EBT | 79.75% | 81.63% | 79.12% | 75.67% | 72.42% |
| EBT Per EBIT | 99.39% | 98.21% | 94.65% | 89.48% | 116.32% |
| Return on Assets (ROA) | 11.41% | 12.77% | 9.39% | 1.85% | 4.07% |
| Return on Equity (ROE) | 18.62% | 18.23% | 13.44% | 2.65% | 5.79% |
| Return on Capital Employed (ROCE) | 16.86% | 19.47% | 14.93% | 3.02% | 5.61% |
| Return on Invested Capital (ROIC) | 12.91% | 14.46% | 11.60% | 2.19% | 4.28% |
| Return on Tangible Assets | 27.87% | 27.18% | 24.24% | 10.53% | 21.39% |
| Earnings Yield | 9.26% | 13.45% | 16.40% | 3.03% | 5.93% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.56 | 5.78 | 5.96 | 3.01 | 4.64 |
| Payables Turnover | 19.07 | 17.28 | 14.00 | 11.83 | 11.08 |
| Inventory Turnover | 4.61 | 4.48 | 3.39 | 5.51 | 6.09 |
| Fixed Asset Turnover | 4.82 | 4.79 | 4.24 | 2.24 | 3.15 |
| Asset Turnover | 0.47 | 0.51 | 0.47 | 0.30 | 0.37 |
| Working Capital Turnover Ratio | 4.15 | 4.93 | 4.59 | 2.87 | 3.82 |
| Cash Conversion Cycle | 162.49 | 123.42 | 142.86 | 156.77 | 105.70 |
| Days of Sales Outstanding | 102.44 | 63.11 | 61.21 | 121.38 | 78.71 |
| Days of Inventory Outstanding | 79.19 | 81.44 | 107.72 | 66.23 | 59.91 |
| Days of Payables Outstanding | 19.14 | 21.13 | 26.08 | 30.84 | 32.93 |
| Operating Cycle | 181.62 | 144.55 | 168.93 | 187.61 | 138.63 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.19 | 0.28 | 0.22 | 0.07 | 0.16 |
| Free Cash Flow Per Share | 0.15 | 0.25 | 0.20 | 0.06 | 0.15 |
| Dividend Paid and CapEx Coverage Ratio | 0.74 | 2.28 | 3.04 | 8.50 | 11.58 |
| Capital Expenditure Coverage Ratio | 4.58 | 10.80 | 18.72 | 8.50 | 17.94 |
| Operating Cash Flow Coverage Ratio | 0.39 | 1.32 | 1.43 | 0.28 | 0.81 |
| Operating Cash Flow to Sales Ratio | 0.18 | 0.29 | 0.29 | 0.15 | 0.28 |
| Free Cash Flow Yield | 5.50% | 14.04% | 22.75% | 6.51% | 14.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.64 | 7.46 | 6.10 | 33.03 | 16.86 |
| Price-to-Sales (P/S) Ratio | 2.60 | 1.87 | 1.23 | 2.00 | 1.85 |
| Price-to-Book (P/B) Ratio | 2.01 | 1.36 | 0.82 | 0.88 | 0.98 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 18.20 | 7.12 | 4.40 | 15.36 | 6.99 |
| Price-to-Operating Cash Flow Ratio | 14.23 | 6.46 | 4.16 | 13.55 | 6.60 |
| Price-to-Earnings Growth (PEG) Ratio | 2.55 | 0.12 | 0.05 | 3.63 | 0.13 |
| Enterprise Value Multiple | 8.06 | 4.80 | 3.57 | 11.37 | 8.89 |
| Enterprise Value | 2.45B | 1.43B | 788.11M | 956.51M | 990.46M |
| EV to EBITDA | 8.06 | 4.80 | 3.57 | 11.37 | 8.89 |
| EV to Sales | 2.93 | 1.83 | 1.22 | 2.36 | 1.90 |
| EV to Free Cash Flow | 20.49 | 6.96 | 4.35 | 18.06 | 7.19 |
| EV to Operating Cash Flow | 16.02 | 6.31 | 4.12 | 15.94 | 6.79 |
| Tangible Book Value Per Share | 0.11 | 0.42 | 0.19 | -0.14 | -0.12 |
| Shareholders’ Equity Per Share | 1.32 | 1.32 | 1.10 | 1.04 | 1.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.16 | 0.17 | 0.23 | 0.17 |
| Revenue Per Share | 1.02 | 0.95 | 0.73 | 0.45 | 0.58 |
| Net Income Per Share | 0.25 | 0.24 | 0.15 | 0.03 | 0.06 |
| Tax Burden | 0.80 | 0.82 | 0.79 | 0.76 | 0.72 |
| Interest Burden | 0.99 | 0.98 | 0.95 | 0.88 | 0.93 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.25 | 0.24 | 0.06 | 0.11 | 0.10 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Income Quality | 0.76 | 0.94 | 1.47 | 2.44 | 2.56 |
Currency in HKD
